Executive Briefings

Ariba Offers Remedy for Prescription Drug Ills

With expiring patents and growing gaps in revenue a reality in today's global pharmaceutical industry, an increasing number of drug manufacturers are beginning to evaluate their supply chains to identify any and all opportunities for savings so that they can continue to bring innovative products to market and remain competitive. With greater frequency, pharmaceutical firms are seeking new sources that can deliver key inputs such as active pharmaceutical ingredients (APIs) at a lower total cost than their current suppliers. And in many cases, they are looking abroad. While there are great gains to be had from sourcing in low-cost countries, there is also substantial risk. Click here for more.

With expiring patents and growing gaps in revenue a reality in today's global pharmaceutical industry, an increasing number of drug manufacturers are beginning to evaluate their supply chains to identify any and all opportunities for savings so that they can continue to bring innovative products to market and remain competitive. With greater frequency, pharmaceutical firms are seeking new sources that can deliver key inputs such as active pharmaceutical ingredients (APIs) at a lower total cost than their current suppliers. And in many cases, they are looking abroad. While there are great gains to be had from sourcing in low-cost countries, there is also substantial risk. Click here for more.